SANTA CLARA, Calif., July 30 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI - News) a cardiac diagnostic and services company, today announced that a top-five pharmaceutical company has named NewCardio’s QTinno(TM) software suite, NewCardio’s first commercial product, as the technology that will be used in all of its fully automated Thorough QT (TQT) studies.
